Biotest AG / Research Update
Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
Biotest awarded patent protection in the USA
· Patent prosecution for BT-061 successfully completed by US authorities
· Decision confirms innovative character of the monoclonal antibody
· Comprehensive protection against generic drugs
Dreieich, 29 July 2008. Biotest's BT-061 monoclonal antibody has been
recognised as an innovative development and awarded comprehensive patent
protection in the USA. Accordingly, a notice of allowance has been issued
to Biotest by the responsible authorities in the United States. The patent
covers BT-061 as a substance and its use in a drug. Consequently, the
monoclonal antibody, developed in the lead indications of rheumatoid
arthritis and psoriasis, is protected against generic drugs in the USA.
Biotest has already been awarded patent protection for BT-061 in several
countries and further patent applications are currently under review
The decision taken by the US patent office to grant the application has
confirmed the innovative character of the antibody. The patent marks a key
milestone in the development of BT-061 and protects marketing of the
product in the world's most important pharmaceutical market.
In the beginning of the current year, Biotest significantly enlarged the
patent portfolio for BT-061 by submitting additional patent applications.
The applications include coverage for therapeutic use and have not yet been
published by the respective patent office. Moreover, further international
applications have recently been added to the patent portfolio for Biotest's
BT-062 antibody (lead indication multiple myeloma).
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and asset
situation of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
Biotest AG, Dreieich, Germany, is a company that researches and
manufactures pharmaceutical, biotherapeutic and diagnostic products and has
specialised in immunology and haematology. In its Pharmaceutical segment,
Biotest develops immunoglobulins, clotting factors and albumins based on
human blood plasma. These are used for diseases of the immune system or
haematopoietic system. In the Biotherapeutic segment, Biotest researches
into the clinical development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and blood cancer. The Diagnostic
segment spans reagents and immunological diagnostics which are used, for
example, in blood transfusions and transplants. Biotest has around 1,850
employees worldwide and its shares are listed in the Stock Exchange's SDAX.
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Michael Ramroth
Tel: +49 (0) 6103 801-338
Fax: +49 (0) 6103 801-347
WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard/official trading
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
29.07.2008 Financial News transmitted by DGAP
Issuer: Biotest AG
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-8 80
ISIN: DE0005227201, DE0005227235
WKN: 522720, 522723
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service